Syndax Pharmaceuticals (SNDX) Amortization of Deferred Charges (2024 - 2026)

Syndax Pharmaceuticals' Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $56000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 50.0% year-over-year to $56000.0; the TTM figure through Mar 2026 stood at $172000.0 (up 21.13% YoY), while the FY2025 annual figure was $228000.0, up 660.0% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $56000.0, up from -$1000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $112000.0 in Q1 2025, with the low at -$1000.0 in Q4 2025.
• The 3-year median for Amortization of Deferred Charges is $55500.0 (2025), against an average of $52333.3.
• The sharpest annual moves came in 2025 and 2026: Amortization of Deferred Charges tumbled 103.33% in 2025, then plunged 50.0% in 2026.
• Syndax Pharmaceuticals' Amortization of Deferred Charges stood at $30000.0 in 2024, then plunged by 103.33% to -$1000.0 in 2025, then soared by 5700.0% to $56000.0 in 2026.
• Business Quant data shows SNDX's Amortization of Deferred Charges at $56000.0 in Q1 2026, -$1000.0 in Q4 2025, and $62000.0 in Q3 2025.